SynthesisFrontiers in neurology2026
Safety and efficacy of idarucizumab-assisted thrombolysis in dabigatran-related acute ischemic stroke: a systematic review and single-arm meta-analysis.
Synthesis in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS) related to dabigatran use requires prior anticoagulation reversal. This study aimed to evaluate the safety and efficacy of IVT following idarucizumab-mediated reversal through a systematic single-arm meta-analysis. Methods: We systematically searched multiple databases. Single-arm studies (≥5 patients) on idarucizumab-facilitated IVT for dabigatran-related AIS were included. Outcome data from DOAC patients without reversal in the Meinel 2023 cohort ( Results: Eleven single-arm studies (226 patients) were included. The pooled sICH rate was 5.4% (95% CI 2.6-10.6%; Conclusion: Current evidence is insufficient to guide routine clinical practice. However, these findings provide useful effect-size estimates (sICH ~5%, good outcome ~67%) for designing future randomised controlled trials. Multicenter prospective registries or pragmatic RCTs are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.